Nutriventia Ltd. has received approval from Health Canada for Prolanza, a clinically-studied sustained-release ashwagandha ingredient. The ingredient has received a natural product number, authorizing its sale as a licensed natural health product.

Health Canada’s approval recognizes the safety, quality, and efficacy of the ingredient, allowing it to be marketed to Canadian consumers. In 300 mg capsules, the ingredient has been shown to help manage measures of sleep, stress, and visual memory.

“This approval marks a significant milestone in Nutriventia’s global mission to deliver scientifically validated, consumer-centric natural ingredients,” said Vishal Shah, co-founder of Nutriventia. “With Prolanza, we bring the next generation of ashwagandha to Canada, combining traditional wisdom with modern delivery technology. As more people are expected to add ashwagandha to their daily self-care routines, we are excited that Canadian consumers may now enjoy the benefits of Prolanza in an easy-to-consume low dose. They can also be assured of its efficacy as demonstrated by our clinical trials.”

Prolanza was made using the company’s E.D.G.E. platform to offer sustained-release benefits. It will be available to formulation partners in Canada across capsules, tablets, gummies, and other modern delivery formats.